HVO vs. OXB, HZD, FARN, VRP, ARIX, CIR, BVXP, 4BB, AVCT, and TILS
Should you be buying hVIVO stock or one of its competitors? The main competitors of hVIVO include Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Circassia Group (CIR), Bioventix (BVXP), 4basebio (4BB), Avacta Group (AVCT), and Tiziana Life Sciences (TILS). These companies are all part of the "biotechnology" industry.
hVIVO vs. Its Competitors
Oxford Biomedica (LON:OXB) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.
64.1% of Oxford Biomedica shares are held by institutional investors. Comparatively, 34.9% of hVIVO shares are held by institutional investors. 21.2% of Oxford Biomedica shares are held by company insiders. Comparatively, 14.0% of hVIVO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Oxford Biomedica had 1 more articles in the media than hVIVO. MarketBeat recorded 1 mentions for Oxford Biomedica and 0 mentions for hVIVO. Oxford Biomedica's average media sentiment score of 1.05 beat hVIVO's score of 0.00 indicating that Oxford Biomedica is being referred to more favorably in the media.
hVIVO has a net margin of 25.96% compared to Oxford Biomedica's net margin of -145.98%. hVIVO's return on equity of 47.93% beat Oxford Biomedica's return on equity.
Oxford Biomedica has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, hVIVO has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.
hVIVO has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks.
Oxford Biomedica presently has a consensus price target of GBX 380, suggesting a potential upside of 13.60%. Given Oxford Biomedica's higher probable upside, equities analysts clearly believe Oxford Biomedica is more favorable than hVIVO.
Summary
Oxford Biomedica and hVIVO tied by winning 8 of the 16 factors compared between the two stocks.
Get hVIVO News Delivered to You Automatically
Sign up to receive the latest news and ratings for HVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (LON:HVO) was last updated on 7/5/2025 by MarketBeat.com Staff
